Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Peritoneal Neoplasms 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

tremelimumab 1poly(I).poly(c12,U) 1olaparib 1lentiviral minigene vaccine of COVID-19 coronavirus 1genexol-PM 1abagovomab 1Topotecan 1Paclitaxel 1Oxaliplatin 1MOC31PE immunotoxin 1LY-2157299 1Introns 1Interferon alpha-2 1Hyperthermic Intraperitoneal Chemotherapy 1Gefitinib 1Drug Therapy 1Doxorubicin 1Cytoreduction Surgical Procedures 1Cisplatin 1Celecoxib 1Capecitabine 1Bevacizumab 1AlkB Homolog 2, Alpha-Ketoglutarate-Dependent Dioxygenase 1Acids 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Peritoneal Neoplasms × abagovomab × Clear all
NCT00103545 2006-10-02

Use of ACA 125 in Patients With Ovarian Cancer: Safety and Immune Response

AGO Study Group

Phase 1/2 Completed
36 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡